Quick Links

Testing AG019 and teplizumab in newly diagnosed type 1 diabetes patients

Testing AG019 and teplizumab in newly diagnosed type 1 diabetes patients

AG019 is a new drug that may interrupt the autoimmune attack on insulin-producing cells in the pancreas during type 1 diabetes. The drug teplizumab (Anti-CD3) has shown value in earlier studies in preserving insulin-producing cells.

The purpose of this study is to investigate if two different doses of AG019 are safe and tolerable when given alone or in combination with teplizumab, in patients recently diagnosed with type 1 diabetes.

Participant Eligibility

You may be eligible to participate if:

– you are 12 year to 40 years old.
– you have been diagnosed with type 1 diabetes within 120 days.
– you test positive for at least one diabetes-related autoantibody.
– you are in good general health.

Contact

Nancy Wickstrom
(206) 287-5633

Additional Study Details

Full Study Title
A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recently Diagnosed Type 1 Diabetes Mellitus (T1D)

Study ID: AG019-T1D-101
Start Date: 10/08/2018
End Date: 06/30/2020

Investigator(s)
Investigator: Carla Greenbaum, MD

Accepts Healthy Volunteers?
No

Study Site(s)

Benaroya Research Institute

1201 Ninth Ave
Seattle, Washington 98101



Interested?

Use the link below to send a message to the study coordinator, or call the number above to speak directly with a study representative.

I am interested in this research study.

SITE PARTNERS
uw-footer